Reviewing Adhera Therapeutics (OTCMKTS:ATRX) & Synaptogenix (NASDAQ:SNPX)

Adhera Therapeutics (OTCMKTS:ATRX) and Synaptogenix (NASDAQ:SNPX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Adhera Therapeutics and Synaptogenix”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adhera Therapeutics	N/A	N/A	-$2.11 million	N/A	N/A
Synaptogenix	N/A	N/A	-$6.04 million	N/A	N/A

Institutional & Insider Ownership

10.3% of Synaptogenix shares are owned by institutional investors. 28.2% of Adhera Therapeutics shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Adhera Therapeutics has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Profitability

This table compares Adhera Therapeutics and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adhera Therapeutics	N/A	N/A	N/A
Synaptogenix	N/A	-42.14%	-29.42%

Analyst Recommendations

This is a summary of current ratings for Adhera Therapeutics and Synaptogenix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adhera Therapeutics	0	0	0	0	0.00
Synaptogenix	0	0	1	0	3.00

Synaptogenix has a consensus target price of $14.00, suggesting a potential upside of 351.61%. Given Synaptogenix’s stronger consensus rating and higher probable upside, analysts clearly believe Synaptogenix is more favorable than Adhera Therapeutics.

Summary

Adhera Therapeutics beats Synaptogenix on 5 of the 9 factors compared between the two stocks.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.